Trials / Completed
CompletedNCT03372200
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Mochida Pharmaceutical Company, Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FYU-981 | Oral daily dosing for 14 weeks |
| DRUG | Febuxostat | Oral daily dosing for 14 weeks |
Timeline
- Start date
- 2018-01-09
- Primary completion
- 2018-06-04
- Completion
- 2018-07-05
- First posted
- 2017-12-13
- Last updated
- 2018-09-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03372200. Inclusion in this directory is not an endorsement.